Talphera, Inc. Common Stock
TLPHStock
$1.35+229.22%52W
Market Cap$74.74M
P/E—
Div yield—
Beta0.76
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)4.83%
Price vs S&P 500 (4W)55.72%
VGM Score72.86
Market Capitalization$74.74M
Earnings Surprise History
Q1 26-0.04est. -0.07
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.13
4.13
4.13
4.11
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TLPHTalphera, Inc. Common Stock | B | C | A | $1.35 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Talphera Inc. is a pharmaceutical company developing therapies for medically supervised clinical settings. Its pipeline centers on nafamostat product candidates, including Niyad and LTX-608, with a focus on pre-filled syringe formulations to optimize drug delivery.